StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.

doi:10.1002/cam4.1037

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.

Cancer medicine - 1 May 2017

Sen Manimala, Katragadda Shanmukh, Ravichandran Aarthi, Deshpande Gouri, Parulekar Minothi, Nayanala Swetha, Vittal Vikram, Shen Weiming, Phooi Nee Yong Melanie, Jacob Jemima, Parchuru Sravanthi, Dhanuskodi Kalpana, Eyring Kenneth, Agrawal Pooja, Agarwal Smita, Shanmugam Ashwini, Gupta Satish, Vishwanath Divya, Kumari Kiran, Hariharan Arun K, Balaji Sai A, Liang Qiaoling, Robolledo Belen, Gauribidanur Raghavendrachar Vijayashree, Oomer Farooque Mohammed, Buresh Cary J, Ramamoorthy Preveen, Bahadur Urvashi, Subramanian Kalyanasundaram, Hariharan Ramesh, Veeramachaneni Vamsi, Sankaran Satish, Gupta Vaijayanti

Abstract excerpt

Comprehensive genetic profiling of tumors using next-generation sequencing (NGS) is gaining acceptance for guiding treatment decisions in cancer care. We designed a cancer profiling test combining both deep sequencing and immunohistochemistry (IHC) of relevant cancer targets to aid therapy choices in both standard-of-care (SOC) and advanced-stage treatments for solid tumors. The SOC report is provided in a short...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Neoplasms

Share to Reproducibility of Results

Share to Translocation, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28371134
DOI: 10.1002/cam4.1037
PMCID: PMC5430095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.PMID 28371134Read ↗

Current practices and guidelines for clinical next-generation sequencing oncology testing.Semantic proximity Read ↗

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging ApplicationsSemantic proximity Read ↗

Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapySemantic proximity Read ↗

Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directionsSemantic proximity Read ↗

How to read a next-generation sequencing report—what oncologists need to knowSemantic proximity Read ↗

Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patientsSemantic proximity Read ↗

Next-generation sequencing to guide cancer therapySemantic proximity Read ↗

Clinical Utility of Large Next-Generation Sequencing Panel Across Diverse Tumour Types: A Single-Center Retrospective Analysis.Semantic proximity Read ↗

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologySemantic proximity Read ↗

A Canadian Guideline on the Use of Next-Generation Sequencing in OncologySemantic proximity Read ↗

Precision oncology: separating the wheat from the chaffSemantic proximity Read ↗

Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.